Press Release
Daré Bioscience, Inc. Announces Effective License and Collaboration Agreement for Topical Sildenafil for Female Sexual Arousal Disorder
Daré announced a license and development agreement with Strategic Science & Technologies to develop SST-6007 earlier this week. SST-6007 incorporates sildenafil, the same active ingredient in Viagra®, in a proprietary cream formulation that is specifically designed to locally increase blood flow to the vulvar-vaginal tissue in women, leading to a potential improvement in genital arousal response and overall sexual experience. If approved, Daré believes SST-6007 would be the first
Daré plans to pursue the 505(b)(2) regulatory pathway for SST-6007 in the U.S. and leverage the existing data and established safety profile of the Viagra® brand. Daré anticipates commencing a Phase 2b clinical trial in the second half of 2018 utilizing the proceeds from the investment that closed today.
SST-6007 is the second product in Daré’s growing portfolio of novel therapeutic candidates that address unmet needs in women’s reproductive and sexual health. Daré’s first product candidate undergoing clinical development in
“The addition of Topical Sildenafil to our portfolio reflects our commitment to develop unique and differentiated products for women’s reproductive health, including contraception, sexual health and vaginal health. Our innovative pipeline of products has the opportunity to unlock value for Daré’s equityholders and deliver medicines that are more aligned with women’s specific needs. We continue actively identifying and evaluating additional candidates that, like Ovaprene™ in contraception and Topical Sildenafil for FSAD, have the potential to address important gaps in the treatment options, ” said
About
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. The company is driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. Daré’s lead product candidate, Ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies. The company is headquartered in
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995 regarding matters that are not historical facts, including statements relating to Daré's expectations regarding the anticipated market demands for its products, the safety and effectiveness of its products, market acceptance of Daré's products and the qualifications and expertise of Daré's management team. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation and completion of clinical trials; availability and timing of data from ongoing and future clinical trials and the results of such trials; whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals; claims of infringement and other risks relating to Daré's owned and licensed intellectual property rights, and other factors discussed in the "Risk Factors" section of Daré's Quarterly Report on Form 10-Q filed with the
Media Contact:
Vice President
Canale Communications
Amanda@canalecomm.com
781-405-8775
Source: Daré Bioscience
Source: Dare Bioscience, Inc.